 |
|
|
| |
Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine and ribavirin with or without peginterferon alfa-2a (40KD) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study
|
| |
| |
Reported by Jules Levin
AASLD 2012 Nov 9-13 Boston
J.J. Feld, I.M. Jacobson, D.M. Jensen, G.R. Foster, S. Pol, E. Tam, H. Berak, J.M. Vierling, J.A. Tavel, M.T. Navarro, S. Shahdad, R. Kulkarni, S. Le Pogam, I. Najera, C.Y. Lim, N.S. Shulman, E.S. Yetzer
from Jules: Roche has ongoing the Annapurna Study which looks at 4 orals: PI, non-nuc polymerase, nuc, rbv
http://www.natap.org/2012/HCV/090412_01.htm
|
| |
|
|
|
|
|
